A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations. (October 2022)

Record Type:: Journal Article
Title:: A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations. (October 2022)
Main Title:: A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
Authors:: Opdam, F.
Heymach, J.
Barve, M.
Wu, Y.L.
Gibson, N.
Sadrolhefazi, B.
Serra, J.
Yoh, K.
Yamamoto, N.
Abstract:
Is Part Of:: European journal of cancer. Volume 174(2022)Supplement 1
Journal:: European journal of cancer
Issue:: Volume 174(2022)Supplement 1
Issue Display:: Volume 174, Issue 1 (2022)
Year:: 2022
Volume:: 174
Issue:: 1
Issue Sort Value:: 2022-0174-0001-0000
Page Start:: S1
Page End:
Publication Date:: 2022-10
Subjects:: Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:: http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0959-8049(22)00811-5 ↗
Languages:: English
ISSNs:: 0959-8049
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 24177.xml